Ascletis Reports Preclinical Data For Oral Obesity Candidate ASC36o

(RTTNews) - Ascletis Pharma Inc. (1672.HK, ASCLF.PK), a biotechnology company, reported preclinical data for ASC36o, a once-weekly oral amylin receptor peptide agonist being developed for obesity and metabolic diseases.

Read at source